Recent Updates
Recently added Catalysts
JAZZ Positive Sentiment Score: 60/100

Jazz Pharmaceuticals to Report 2023 First Quarter Financial Results on May 10, 2023 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2023 first quarter financial results on Wednesday, May 10, 2023,...

Wednesday, April 26, 2023 2 min read
Key Takeaway: Jazz Pharmaceuticals has announced that it will report its 2023 first quarter financial results on May 10, 2023, following the close of U.S. financial markets. Management will host a live audio webcast at 4:30 p.m. ET to discuss the results and provide a business update. Interested parties can register for the call in advance on the company's website, and a replay will also be available. Jazz is committed to developing transformative medicines within the fields of neuroscience and oncology.

Market Sentiment Analysis

POSITIVE FACTORS

  • Jazz Pharmaceuticals is reporting its first quarter financial results, indicating ongoing business activity.
  • The live audio webcast suggests transparency and engagement with investors.
  • The company continues to innovate in developing life-changing medicines.

Full Press Release Details

DUBLIN , April 26, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it will report its 2023 first quarter financial results on Wednesday, May 10, 2023 , after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. IST to discuss 2023 first quarter financial results and provide a business and financial update.
Interested parties may register for the call in advance here or via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com . To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.
A replay of the webcast will be available via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com .
About Jazz Pharmaceuticals Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases – often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in neuroscience and oncology. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in nearly 75 countries. Please visit www.jazzpharmaceuticals.com for more information.
Investors: Andrea N. Flynn , Ph.D. Vice President, Head, Investor Relations Jazz Pharmaceuticals plc [email protected] Ireland +353 1 634 3211 U.S. +1 650 496 2717
Media Contact: Kristin Bhavnani Head of Global Corporate Communications Jazz Pharmaceuticals plc [email protected] Ireland +353 1 637 2141 U.S. +1 215 867 4948
SOURCE Jazz Pharmaceuticals plc

21 %

Frequently Asked Questions

When will Jazz Pharmaceuticals report its financial results?

Jazz Pharmaceuticals will report its Q1 2023 financial results on May 10, 2023.

What time is the webcast for the financial results?

The webcast will take place at 4:30 p.m. ET / 9:30 p.m. IST.

How can I register for the webcast?

You can register for the call via the Investors section of Jazz's website.

Will the webcast be available after the event?

Yes, a replay of the webcast will be accessible on their website.

What does Jazz Pharmaceuticals focus on?

Jazz Pharmaceuticals focuses on developing medicines for serious diseases.

Tags: JAZZ Viatris Investor Conferences Healthcare Jazz Pharmaceuticals financial results biopharmaceuticals Q1 2023
Last updated: Apr 26, 2023